RxDoctor Payments DataLook up a doctor →

Phuong Trinh

Infectious Disease · Silver Spring, MDNPI 1679536486

Payments from drug & device makers

$196,007in general payments, 2019–2025

Across 855 payments — averaging $229.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$97K
  • Gilead$91K
  • AbbVie$1K
  • Merck$923
  • Insmed, Inc.$762
  • Adaptive Biotechnologies Corporation$757
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$10,2705%
  • Speaking & faculty fees$157,94981%
  • Travel & lodging$6,1363%
  • Food & beverage$21,25811%
  • Education$3940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$196,007 in reported general payments places this provider in the 85th percentile of 289 infectious disease providers in Maryland.

See all infectious disease providers in Maryland

Medicare billing

Part B allowed, 2024
$90,880
Medicare patients
421
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala328$1,431,296
OdefseyEmtricitab/Rilpiviri/Tenof Ala160$715,132
DovatoDolutegravir Sodium/Lamivudine101$293,263
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf20$93,402
DescovyEmtricitabine/Tenofov Alafenam37$89,186
PrezcobixDarunavir/Cobicistat20$61,123
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,561
TivicayDolutegravir Sodium15$33,412
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df22$10,241
Atorvastatin Calcium104$1,156
Rifampin22$975
Levothyroxine Sodium20$285
Metformin Hcl ErMetformin Hcl19$247
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril12$154
Pravastatin Sodium14$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$91,366$1,520,482365 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay$97,448$367,236127 claims
Janssen Products, LPSymtuza$540$93,40220 claims
Johnson & JohnsonPrezcobix$621$61,12320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 infectious disease providers in Maryland.

Other infectious disease in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →